'Does that look like vaccine success?': Johnson 'exposes' Pfizer, Moderna at Senate COVID hearing

Overview

The hearing discussion argues that COVID-19 vaccine rollouts were not “successful” in the way official narratives claim. It further contends that key safety and effectiveness data were mishandled, selectively interpreted, or presented in misleading ways.

Effectiveness vs. pandemic trajectory (cases/variants)

• A chart reportedly showing daily new COVID cases peaking around January 2021 (when vaccination uptake began) is used to question whether vaccines stopped the pandemic or merely coincided with ongoing waves.
• The speaker argues that later waves—especially Delta and Omicron—still occurred, which they say conflicts with the claim that vaccines ended the crisis.

Criticism of government pandemic strategy

A physician-contributor argues that the UK/England experience (used as an analogy) shows:

• COVID waves naturally peak and fade.
• Lockdowns were implemented too late, after the first wave was already disappearing.
• Vaccines were introduced as the second wave was falling, contributing to exaggerated claims that interventions “saved millions,” heavily based on computer modeling.

Challenge to “millions of lives saved” estimates

• A Commonwealth Fund study is cited as claiming 3.2 million lives saved in 2021–2022.
• The speaker rebutts this with “simple math,” comparing:
  • historical death trends (e.g., about 2.85 million deaths in 2019), with
  • COVID-era death totals (claims roughly 3.5 million in 2021 and 3.3 million in 2022).
• The argument presented is that there is “no way” the study’s implied counterfactual (what would have happened without vaccines) holds up.

VAERS safety concerns as evidence of harm

The discussion points to VAERS data to argue that harm may have increased around vaccination campaigns:

• Deaths reported to VAERS are claimed to have risen dramatically after vaccination began (figures described as tens of thousands worldwide).
• About a quarter (24%) of reported deaths are claimed to have occurred within 1–2 days of vaccination.

The speaker acknowledges this does not prove causation, but argues regulators still should have investigated further and warned the public.

Allegations of trial/design manipulation

A contributor claims that clinical trials and analyses were structured in ways that downplayed early deaths, including:

• People dying within 1–2 days of vaccination allegedly being categorized as “unvaccinated,” based on efficacy timelines tied to immune response onset.

Relative vs. absolute benefit

Another major critique is that approvals relied heavily on relative risk reduction (e.g., “95%”), while the absolute risk was much smaller. This leads to a claim of:

• a high “number needed to vaccinate” to prevent benefit (stated as about 1 in 118).

Cancer / spike protein claims

The panel questions claims about the lack of evidence regarding vaccine-linked spike protein persistence:

• It is argued to be “unexpected” to find spike protein in tumors (as reported via biopsies).
• Concerns are raised about insufficient forensic examination of deceased patients to determine how spike protein could be present years later.
• One speculative explanation offered is that modified mRNA or spike expression could persist and later associate with tumor growth.

Broader trust and safety surveillance argument

Contributors repeatedly claim there was:

• “obfuscation” of data, and
• insufficient safety surveillance.

They also allege that large-scale spike protein testing is not available at the scale needed to evaluate long-term consequences, in contrast to other disease markers (e.g., hepatitis).

Presenters or contributors

• Dr. Dalgliesh
• Aaron Siri (referenced as having urged review; not shown as speaking)
• Commonwealth Fund (study referenced)
• “Johnson” (implied by the video title; not explicitly heard in the provided subtitles but referenced)